Target (abbrv.) |
VEGF sR2 |
Target (full name) |
Vascular endothelial growth factor receptor 2 |
Somalogic ID (Sequence ID) |
SL003201 (3651-50_5) |
Entrez Gene Symbol |
KDR |
UniProt ID |
P35968 |
UniProt Comment |
- Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
|
Targeted by drugs (based on IPA annotation) |
- AEE 788
- sunitinib
- cediranib
- pazopanib
- axitinib
- XL647
- CEP 7055
- brivanib alaninate
- CHIR-265
- tivozanib
- motesanib
- OSI-930
- telatinib
- ramucirumab
- cabozantinib
- nintedanib
- regorafenib
- bortezomib/sorafenib
- lapatinib/pazopanib
- dexamethasone/lenalidomide/sorafenib
- bevacizumab/sorafenib
- cabozantinib/erlotinib
- docetaxel/ramucirumab
- vatalanib
- sorafenib
- vandetanib
- pegaptanib
|
Biomarker applications (based on IPA annotation) |
- disease progression
- efficacy
- prognosis
- response to therapy
- safety
|
Wiki Pathways |
- Angiogenesis
- Focal Adhesion
- angiogenesis overview
|
Pathway Interaction Database |
- Beta3 integrin cell surface interactions
- HIF-2-alpha transcription factor network
- Integrins in angiogenesis
- Notch-mediated HES/HEY network
- S1P1 pathway
- SHP2 signaling
- Signaling events mediated by TCPTP
- Signaling events mediated by VEGFR1 and VEGFR2
- VEGF and VEGFR signaling network
|
Reactome |
- EPHA-mediated growth cone collapse
- Integrin cell surface interactions
- Neurophilin interactions with VEGF and VEGFR
- VEGF binds to VEGFR leading to receptor dimerization
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
|
Pathway Studio |
- Transcytosis
- VEGFR → AP-1/CREB/MYC signaling
- VEGFR → ATF/CREB/ELK-SRF signaling
- VEGFR → CTNNB signaling
- VEGFR → CTNND signaling
- VEGFR → FOXO3A signaling
- VEGFR → NFATC signaling
- VEGFR → STAT signaling
|